LCN2 and metabolic dysfunction-associated steatotic liver disease: Based on the fact that expression profiles between HCC samples differ based on the cancer origin, it would be interesting to see whether LCN2 is a marker, which rises during NAFLD-induced HCC pathogenesis, and, if so, solely or as a part of a general modified gene profile.